News

Viking Therapeutics Achieves Key Milestones in Q2 2025

Viking Therapeutics Achieves Key Milestones in Q2 2025

Viking Therapeutics Reports Financial Results and Updates on Clinical Developments

Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company, has announced key financial findings and significant progress in its clinical trials for the second quarter of 2025.

Key Highlights from Q2 2025

Viking Therapeutics experienced notable achievements during the second quarter, as reflected in their financial reporting. The company ended the quarter with a robust cash position of $808 million, which will support ongoing clinical developments.

CEO Brian Lian, Ph.D., discussed the successful execution of key clinical milestones, particularly regarding VK2735, their leading drug candidate aimed at obesity management. The initiation of the Phase 3 VANQUISH registration trials marks a pivotal step in this program, showcasing Viking's dedication to addressing metabolic disorders.

Initiation of Phase 3 Trials

The Phase 3 VANQUISH trials involve two distinct studies focusing on VK2735. One trial targets patients with obesity, while the other includes patients with type 2 diabetes who also struggle with obesity. These randomized, double-blind studies are designed to evaluate the effectiveness and safety of VK2735 administered weekly via subcutaneous injection over a 78-week period.

Preliminary results from earlier phases suggest significant weight loss in patients receiving VK2735 compared to those on placebo. With promising safety profiles observed, these ongoing trials are critical to assessing the drug's efficacy across diverse patient populations.

Progress in VENTURE-Oral Study

In addition to the VANQUISH studies, Viking recently completed enrollment for its Phase 2 VENTURE-Oral dosing trial. This multifaceted study focuses on VK2735 in an oral tablet format, providing an alternative for patients who prefer non-injection therapies.

The VENTURE-Oral trial aims to examine the safety, tolerability, and pharmacokinetics of the oral formulation of VK2735, serving as a potential solution for individuals looking to maintain their weight loss through a convenient dosing regimen.

Amylin Agonist Program Development

Viking has also made strides in advancing its Amylin program, with plans to submit an Investigational New Drug (IND) application later this year, which is expected to further expand their therapeutic offerings in metabolic disorders.

Financial Overview

The financial highlights for the quarter show a rise in research and development expenditures, amounting to $60.2 million, compared to $23.8 million during the same period last year. This escalation reflects increased costs related to clinical studies and drug manufacturing efforts.

As of June 30, 2025, Viking reported a net loss of $65.6 million, or $0.58 per share. This is a significant increase from the previous year's net loss of $22.3 million. The driving factors for this loss primarily stem from the heightened R&D and administrative expenses associated with ongoing trials and operations.

Looking Ahead

Viking Therapeutics is poised for continued growth through its extensive pipeline of innovative therapies for metabolic and endocrine disorders. With the recent financial backing and the commitment to advancing VK2735, the company remains focused on enhancing the lives of patients struggling with obesity and related conditions.

Upcoming Investor Events

Viking's management will participate in several important investor events in the upcoming months, allowing for further engagement with stakeholders and potential investors. These events are crucial for sharing insights and building partnerships that could propel their development efforts forward.

About Viking Therapeutics, Inc.

Viking Therapeutics is dedicated to expert research in metabolic diseases, focusing on innovative therapies like VK2735, aimed at revolutionizing treatment approaches for various metabolic disorders. Their ongoing commitment to R&D promises to yield significant advancements in the field.

Frequently Asked Questions

1. What is the current focus of Viking Therapeutics?

Viking Therapeutics is primarily focused on developing innovative therapies for metabolic and endocrine disorders, including treatments for obesity.

2. What are the recent developments in the VK2735 program?

The VK2735 program has entered Phase 3 trials with the VANQUISH registration studies underway to evaluate its effectiveness and safety in obesity management.

3. What financial results did Viking Therapeutics report for Q2 2025?

Viking reported a net loss of $65.6 million for Q2 2025 and highlighted increased R&D expenditures compared to 2024.

4. How is Viking addressing the need for diverse dosing options?

The company is developing an oral formulation of VK2735, providing patients with a convenient non-injection alternative for weight loss therapy.

5. Where can I find more information about Viking Therapeutics?

For additional details, you can visit their official website, which provides insights into their ongoing programs and corporate updates.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 169

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 82

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
ArcSpan AMS Nabs Top Honors at The Wires 2026

Updated Category News Views 46

ArcSpan Takes Center Stage with Prestigious Accolade ArcSpan just bagged the Best New Product or Service: Sell Side award at The Wires 2026. This ain't your average pat on the back. Taking place at the ritzy One Marylebone in London, this win springs from an event that celebrates the crème de la crème of digital advertising innovation. A Solid Win Amid The Changing Ad...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 84

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 22

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 69

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 189

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 150

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 247

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading

Top 5 Most Recently Viewed Articles

Edward H. McKay Takes Helm as New CEO of Shenandoah Telecommunications

Updated Category News Views 218

Leadership Change at Shenandoah Telecommunications Shenandoah Telecommunications Company, often referred to as "Shentel," has officially announced a significant leadership transition. Edward H. "Ed" McKay has been appointed as the new President and Chief Executive Officer. This change is set to take place on a specified date in the near future, as current President and...

Continue Reading
Projected Growth of Security Printing Market to USD 5.79 Billion

Updated Category News Views 118

Security Printing Market Overview SkyQuest has forecasted that the global security printing market will achieve a remarkable valuation of USD 5.79 billion by the year 2031. This represents a compound annual growth rate (CAGR) of 3.10% during the projection period, which spans from 2024 to 2031. The driving force behind this growth is the collective efforts of governments...

Continue Reading
Prosperity Bancshares, Inc. and Southwest Bancshares Unite

Updated Category News Views 136

Prosperity Bancshares, Inc. Merges with Southwest Bancshares In an exciting development for the banking sector, Prosperity Bancshares, Inc. has officially completed its merger with Southwest Bancshares, Inc. This strategic consolidation promises to bring enhanced customer service and a richer array of financial products, benefiting customers in various ways. As the...

Continue Reading
Revolutionizing AI Security Standards: Wallarm's A2AS Framework

Updated Category News Views 970

Wallarm's Role in Advancing AI Security Today, Wallarm announced its significant contribution to the release of "A2AS: Agentic AI Runtime Security and Self-Defense." This innovative project, spearheaded by Eugene Neelou, aligns various industry leaders, including AWS, Cisco, Google, and more, to fortify the foundation of AI security protocols. The A2AS Framework: A New...

Continue Reading
R2 Wireless Expands Operations with New US Leadership Team

Updated Category News Views 355

R2 Wireless Expands Operations with New Leadership R2 has made a significant stride in addressing the increasing threats and advancements in Electronic Warfare and Counter-UAS programs. The company has launched its US operations and appointed Mr. Cordell Bennigson as its US CEO. Strategic Move for Growth This strategic decision comes in response to the rising global...

Continue Reading